Study |
Etiology |
Patient Characteristics |
N |
Study Design |
Main findings * |
Shaddy et al.
2007 [64] |
Dilated CM and systemic RV |
Age < 13 yrs
LVEF 27%
NYHA class II & III |
161 |
Multicenter RCT
Carvedilol vs. Placebo for 8 months |
No difference. In patients with systemic LV, a trend towards improvement was noted however |
Doughan et al.
2007 [65] |
D-TGA (atrial baffle) |
Adults
RVEF 35%
NYHA class I to III |
60 |
Retrospective study.
4 months
Carvedilol or Metoprolol for |
Beneficial effect: ↓NYHA class especially if pacemaker or initial NYHA class III
Prevents further chamber dilatation |
Josephson et al.
2006 [66] |
D-TGA (atrial baffle) |
Adults
NYHA mainly class II
RV diameter 41.5 mm |
8 |
Retrospective study. Median
FU of 3 yrs
Carvedilol Metoprolol, Sotalol |
Beneficial effect: ↓ NYHA class in 5 patients |
Giardini et al.
2007 [67] |
D-TGA (atrial baffle)
L-TGA |
Age > 18 yrs
NYHA class II & III
RVEF= 34% |
8 |
Single arm prospective
Carvedilol
for 12 months |
Beneficial effect: ↓ RVED volume by 6%, ↑RVEF 6% ‡. No change in peak VO2. |
Norozi et al.
2007 [68] |
Tetralogy of Fallot |
NYHA I and II
Adults
LVEF= 57%
CI = 3.8 L/min/m2 |
33 |
RCT
Bisoprolol vs. placebo for 6 months |
No difference in peak VO2, RVEF, ventricular volumes, NYHA class |